This chapter describes thalidomide embryopathy as a paradigm of exogenous malformation. Previously, 1 in 1000 newborns had a limb anomaly, dreaded by agrarian societies that valued their offspring according to their bodily fitness. During the Middle Ages, malformations were attributed to cohabitation with animals or maternal imagination. Thalidomide, produced by the German company Chemie Grünenthal, was a popular sleeping pill marketed in Germany from 1957, in Britain from 1958, and in many other countries. With a 9-month delay and until 1962, over 10,000 severely malformed infants were born worldwide, the most frequent defects being limb reductions, ear and eye anomalies, and heart malformations. The drug’s toxicity was species specific and acted from 24 to 33 days after fertilization, when many women did not yet know they were pregnant. The epidemic was the greatest disaster in the history of pharmacology, and revealed severe shortcomings in German drug legislation. In the aftermath of this catastrophe, drug laws were tightened and patient safety has improved. The price was that in European countries, it became difficult to develop new drugs for infants.